Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Bolt Biotherapeutics Inc.

    NASDAQ: BOLT · Real-Time Price · USD
    0.29
    -0.03 (-10.44%)
    At close: Jun 05, 2025, 3:59 PM
    0.30
    1.66%
    Pre-market: Jun 06, 2025, 08:23 AM EDT

    Bolt Biotherapeutics Statistics

    Share Statistics

    Bolt Biotherapeutics has 38.34M shares outstanding. The number of shares has increased by 0.56% in one year.

    Shares Outstanding

    n/a
    		 38.34M

    Shares Change (YoY)

    n/a
    		 0.56%

    Shares Change (QoQ)

    n/a
    		 0.17%

    Owned by Institutions (%)

    n/a
    		 48.81%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 638

    FTD / Avg. Volume

    n/a
    		 0.19%

    Short Selling Information

    The latest short interest is 256.53K, so 0.67% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 256.53K

    Short % of Shares Out

    n/a
    		 0.67%

    Short % of Float

    n/a
    		 0.67%

    Short Ratio (days to cover)

    n/a
    		 2.07

    Valuation Ratios

    The PE ratio is -0.32 and the forward PE ratio is -0.33. Bolt Biotherapeutics's PEG ratio is 0.03.

    PE Ratio

    n/a
    		 -0.32

    Forward PE

    n/a
    		 -0.33

    PS Ratio

    n/a
    		 2.66

    Forward PS

    n/a
    		 0.7

    PB Ratio

    n/a
    		 0.36

    P/FCF Ratio

    n/a
    		 -0.33

    PEG Ratio

    n/a
    		 0.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Bolt Biotherapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.2, with a Debt / Equity ratio of 0.44.

    Current Ratio

    n/a
    		 3.2

    Quick Ratio

    n/a
    		 3.2

    Debt / Equity

    n/a
    		 0.44

    Debt / EBITDA

    n/a
    		 -0.38

    Debt / FCF

    n/a
    		 -0.41

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $147,884.62

    Profits Per Employee

    n/a
    		 $-1,213,807.69

    Employee Count

    n/a
    		 52

    Asset Turnover

    n/a
    		 0.08

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -61.33% in the last 52 weeks. The beta is 0.91, so Bolt Biotherapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.91

    52-Week Price Change

    n/a
    		 -61.33%

    50-Day Moving Average

    n/a
    		 0.35

    200-Day Moving Average

    n/a
    		 0.51

    Relative Strength Index (RSI)

    n/a
    		 40.53

    Average Volume (20 Days)

    n/a
    		 331,980

    Income Statement

    In the last 12 months, Bolt Biotherapeutics had revenue of 7.69M and earned -63.12M in profits. Earnings per share was -1.65.

    Revenue

    n/a
    		 7.69M

    Gross Profit

    n/a
    		 5.51M

    Operating Income

    n/a
    		 -73.05M

    Net Income

    n/a
    		 -63.12M

    EBITDA

    n/a
    		 -66.45M

    EBIT

    n/a
    		 -68.24M

    Earnings Per Share (EPS)

    n/a
    		 -1.65
    Full Income Statement

    Balance Sheet

    The company has 7.21M in cash and 25.21M in debt, giving a net cash position of -18M.

    Cash & Cash Equivalents

    n/a
    		 7.21M

    Total Debt

    n/a
    		 25.21M

    Net Cash

    n/a
    		 -18M

    Retained Earnings

    n/a
    		 -427.4M

    Total Assets

    n/a
    		 85.86M

    Working Capital

    n/a
    		 28.95M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -61.29M and capital expenditures -41K, giving a free cash flow of -61.33M.

    Operating Cash Flow

    n/a
    		 -61.29M

    Capital Expenditures

    n/a
    		 -41K

    Free Cash Flow

    n/a
    		 -61.33M

    FCF Per Share

    n/a
    		 -1.61
    Full Cash Flow Statement

    Margins

    Gross margin is 71.64%, with operating and profit margins of -949.91% and -820.78%.

    Gross Margin

    n/a
    		 71.64%

    Operating Margin

    n/a
    		 -949.91%

    Pretax Margin

    n/a
    		 -820.78%

    Profit Margin

    n/a
    		 -820.78%

    EBITDA Margin

    n/a
    		 -864.17%

    EBIT Margin

    n/a
    		 -949.91%

    FCF Margin

    n/a
    		 -797.53%

    Dividends & Yields

    BOLT does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for BOLT is $2.5, which is 762.1% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $2.5

    Price Target Difference

    n/a
    		 762.1%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -8.97

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist